Home > Rheumatology > EULAR 2022 > Antifibrotic therapy also effective in patients with negative prognostic factors for lung function decline

Antifibrotic therapy also effective in patients with negative prognostic factors for lung function decline

Presented By
Prof. Christopher  Denton, University College London, UK
Conference
EULAR 2022
Trial
SENSCIS
Previously, nintedanib has shown to slow lung function decline in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the SENSCIS trial. A post-hoc analysis of this trial revealed that treatment benefit is also evident in patients with 4 characteristics associated with a fast decline of lung function. “The SENSCIS trial reflected a real-world population and allowed broad inclusion criteria,” Prof. Christopher  Denton (University College London, UK) explained [1,2]. “Our analysis aimed to assess the effect of nintedanib on the rate of forced vital capacity (FVC) decline but focusing on subjects with risk factors for rapid FVC decline,” he said. Post-hoc, the rate of decline in FVC (mL/year) over 52 weeks was analysed in subjects with the following 4 risk factors at baseline: early SSc (<18 months since onset of first non-Raynaud symptom); elevated inflammatory markers (CRP ≥6 mg/L and/or platelets ≥330 x 109/L); ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on